|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
52072331
???header.onlineuser??? :
1201
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"botteman m"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-02-25T09:08:37Z |
Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non–Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin
|
Hirsh, V.; Wan, Y.; FANG-JU LIN; Margunato-Debay, S.; Ong, T.J.; Botteman, M.; Langer, C. |
| 國家衛生研究院 |
2016-10 |
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge
|
Pelzer, U;Blanc, JF;Melisi, D;Cubillo, A;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Siveke, JT;Wan, Y;Solem, CT;Botteman, M;Yang, Y;de Jong, F;Hubner, R |
| 國家衛生研究院 |
2016-05 |
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with
|
Pelzer, U;Blanc, JF;Melisi, D;Cubillo, A;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Siveke, JT;Wan, Y;Solem, CT;Botteman, M;Yang, Y;de Jong, F;Hubner, R |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
